Financials

Discussions Technicals Seasonals

6586 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

CHO Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of innovative products based on the proprietary glycan engineering technologies. Its products include CHO-H01 & CHO-H02 antibody for cancer; CHO-H03 antibody for autoimmune disease; CHO-A04 antibody for cancer; and CHO-V08. The company was founded by Kong Ming Lu on March 8, 2013 and is headquartered in Nangang, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

6586 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company